Gene Menendez Email

Regional Business Director . Progenics Pharmaceuticals

Current Roles

Employees:
68
Revenue:
$5.3M
About
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc. company. For additional information, please visit www.progenics.com.
Progenics Pharmaceuticals Address
One World Trade Center
New York, NY
United States
Progenics Pharmaceuticals Email
Progenics Pharmaceuticals Phone Numbers
646-975-2500

Past Companies

Progenics Pharmaceuticals, a Lantheus CompanyRegional Business Director
Spectrum PharmaceuticalsAssociate Director, Lymphoma Accounts
Cell TherapeuticsManager Nuclear Oncology

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.